PREDICTORS OF MORTALITY AND CLINICAL CHARACTERISTICS AMONG CARBAPENEM-RESISTANT OR CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE BLOODSTREAM INFECTION IN SPANISH CHILDREN

María Fátima Ara-Montojo¹, Luis Escosa-García PhD¹, Marina Alguacil², Nieves Seara², Carlos Zozaya³, Diego Plaza⁴, Cristina Schuffelmann-Gutiérrez⁵, Ángela de la Vega⁶, Carlota Fernández-Cambor⁷, Esther Ramos-Boluda⁸, María Pilar Romero-Gómez², Guillermo Ruiz-Carrascoso PhD², Itsaso Losantos-García⁹, María José Mellado-Peña PhD¹, Rosa Gómez-Gil².

1. Paediatric Tropical and Infectious Diseases, Department of Paediatrics, Hospital Universitario La Paz, Madrid, Spain.

2. Department of Microbiology, Hospital Universitario La Paz, Madrid, Spain.

3. Department of Neonatology, Hospital Universitario La Paz, Madrid, Spain.

4. Department of Paediatric Hematology and Oncology, Hospital Universitario La Paz, Madrid, Spain.

5. Paediatric Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain.

6. Department of Hepatology and Liver Transplantation, Hospital Universitario La Paz, Madrid, Spain.

7. Department of Nephrology and Kidney Transplantation, Hospital Universitario La Paz, Madrid, Spain.

8. Paediatric Intestinal Rehabilitation and Bowel Transplantation, Hospital Universitario La Paz, Madrid, Spain.

9. Department of Biostatistics, Hospital Universitario La Paz, Madrid, Spain.

26 **María Fátima Ara-Montojo and Luis Escosa-García contributed equally to this**
 27 **article and both should be considered first author.**

28 **María Fátima Ara-Montojo.** Servicio de pediatría hospitalaria, enfermedades infecciosas
 29 y tropicales. Hospital Universitario La Paz. Paseo de la Castellana 261, C.P. 28046.
 30 Madrid, Spain.
 31 Telephone number: 0034 917277479.
 32 E-mail: fatiaramon@gmail.com

33 **Luis Escosa-García.** Servicio de pediatría hospitalaria, enfermedades infecciosas y
 34 tropicales. Hospital Universitario La Paz. Paseo de la Castellana 261, C.P. 28046. Madrid,
 35 Spain.
 36 Telephone number: 0034 917277479.
 37 E-mail: luisescosa1983@gmail.com

38 **Running title:** “Carbapenem-resistant or carbapenemase-producing Enterobacteriaceae
 39 bloodstream infection in Spanish children”

40 **Funding:** This work was not economical supported by any institution.

41 **Transparency declarations:** None to declare.

42

43

44

45

46

47

48

49

50

51 **Synopsis**

52 **Background:** Carbapenem-resistant Enterobacteriaceae (CRE) are a growing problem in
53 pediatric population worldwide with high mortality rates (18.5-52%) in bloodstream
54 infection (BSI).

55 **Objectives:** The aim of this study is to evaluate predictors of 30-day mortality in CRE BSI
56 in a pediatric cohort.

57 **Methods:** Retrospective observational single-center study (December 2005 - August 2018)
58 was conducted. CRE BSI in children 0 to 16 years were included. Microbiological
59 identification (MALDI Biotyper) and antimicrobial susceptibility testing (Vitek2® and
60 MicroScan panel NBC44) according to current EUCAST breakpoints were performed.
61 PCR OXVIKP® was used to confirm carbapenemases genes (OXA-48, VIM, KPC,
62 NDM). Demographic characteristics, underlying diseases, source of bacteremia,
63 antimicrobial therapy and outcomes were collected from medical records. Survival analysis
64 to establish predictors of 30 day-mortality was performed.

65 **Results:** Thirty-eight cases were included, 76.3% hospital-acquired infections and 23.7%
66 related to healthcare. All patients had underlying comorbidity and 52.6% had received a
67 transplant. VIM-carbapenemase was the predominant mechanism (92%). Previous CRE
68 colonization or infection rate was 52.6%. Gut (26%) and vascular catheter (21%) were the
69 predominant sources of infection. Crude mortality within 30 days was 18.4% (7/38);
70 directly related 30-day mortality was 10.5%. Conditions associated with an increment in
71 30-day mortality were intensive care admission and inadequate empiric therapy ($p<0.05$).
72 Combination antibiotic targeted treatment and a low meropenem MIC were not related to
73 improved survival.

74 **Conclusions:** CRE BSI mortality rate is high. The most important factor related to 30-day
75 survival in our CRE BSI cohort in children was success in empiric treatment with at least
76 one active antibiotic.

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97 Introduction

98 Carbapenem-resistant Enterobacteriaceae (CRE) infections are a growing problem in
 99 pediatric population worldwide. In recent years, an increment in the number of cases has
 100 been reported in many countries.¹⁻² Some risk factors have been identified in previous
 101 studies, including underlying comorbidity, immunosuppression, previous central venous
 102 catheter, endotracheal intubation and prior antibiotic exposure.^{3,4}

103 CRE infections in children have been associated with high mortality rates, up to 52%,
 104 probably due to delays in appropriate antibiotic therapy, lack of available active antibiotics
 105 against CRE, underlying conditions and illness severity.⁵ Therefore, treatment of CRE
 106 infections is a real challenge for clinicians and pediatric antibiotic pipeline is limited. Some
 107 studies in adults suggested that carbapenem-containing combination therapy was
 108 associated with improved survival in severe invasive infections due to CRE.^{6,7} Due to the
 109 lack of studies in children, data to guide management has been extrapolated from adult
 110 literature. Current recommendation in pediatrics is combination therapy of at least two
 111 agents with in vitro activity in most scenarios, until more available data and experience
 112 with newer betalactam agents.⁸⁻¹⁰ To improve management of CRE infections in pediatric
 113 population it is necessary to evaluate if combination therapy is associated with lower
 114 mortality rates than monotherapy for all scenarios.

115 The aim of this study is to evaluate risk factors for CRE bacteremia and independent
 116 predictors of mortality (up to 30 days) related to the infection in a pediatric cohort.

117

118

119

120

Patients and Methods

Study design

A retrospective observational single-center study was conducted.

Setting

Hospital Universitario La Paz (HULP) Children's Hospital is a tertiary hospital with 256 hospitalization beds belonging to the Spanish Health National System, serving more than 45,000 children's emergency and more than 8,000 children's hospital admissions per year in Northern Madrid (Spain). It has a 16-bed pediatric intensive care unit (PICU) and a 23-bed neonatal intensive care unit (NICU), being the National Referral Hospital for pediatric transplantation.

Inclusion and exclusion criteria

Episodes of bloodstream infection (BSI) in children 0 to 16 years of age that showed the growth of CRE were included from December 2005 to August 2018. CRE isolate was defined as any Enterobacteriaceae non-susceptible to meropenem (MIC > 8 mg/L), imipenem (MIC > 2 mg/L) or ertapenem (MIC > 0.5 mg/L), or if carbapenemase production was documented.¹¹ Polymicrobial bacteremia episodes were excluded.

Variables and Data Collection

We collected demographic characteristics, reason for admission and diagnosis, underlying diseases, source of bacteremia, empirical and targeted antimicrobial therapy and outcomes from medical records. Hospital's Microbiology department provided microbiological data.

Definitions

BSI was classified as hospital-acquired, community-acquired or healthcare-associated (HCA) according to classic and modified CDC criteria. Episodes of community-acquired

bacteremia were further classified as healthcare-associated (HCA) if any of the following criteria were present:¹² 48-hours hospital admission during the previous 90 days, receipt of hemodialysis, intravenous medication or home wound care in the previous 30 days or residence in a nursing home or long-term care facility.

Classification as sepsis or septic shock was performed according to definitions of the International Consensus Conference on Pediatric Sepsis.¹³

The primary source of bacteremia was determined by the clinical presentation and/or by the evidence of an identical strain cultured near to or on the same date as the onset of BSI from other body site. To classify an infection as catheter-related BSI the 2009 Infectious Diseases Society of America (IDSA) Guidelines criteria were used.¹⁴ When the source of bacteremia could not be identified, it was classified as primary bacteremia.

According to Hsu AJ et al. recommendations, antimicrobial therapy was considered “microbiologically appropriate” if the patient received one active agent against the isolate (MIC within the susceptible range) and “clinically adequate” if the patient received a combination of two active antibiotics at a right dose and route according to source of infection.⁸ Use of imipenem or meropenem ($\text{MIC} \leq 8 \text{ mcg/ml}$) was considered adequate if high-dosed (25 mg/kg q6h for imipenem, 40 mg/kg over 3 hours q8h for meropenem), adjusted to renal function, and associated with a second microbiologically active agent.

Bacterial isolates and microbiological work-up

Blood cultures were incubated in the Bactec automated blood culture device (BACTEC™, Becton Dickinson, Franklin Lakes, NJ, USA) and BacT/ALERT® (bioMérieux, Marcy l’Etoile, France) blood culture bottle systems. All positive blood cultures were routinely subcultivated on three agar plates: sheep blood agar, chocolate blood agar and *Brucella* blood agar.

Identification was performed by MALDI Biotyper (Bruker Daltonik GmbH, Bremen, Germany) and antimicrobial susceptibility testing (AST) was performed using the automated system Vitek2®, (bioMérieux Marcy l'Etoile, France) and MicroScan panel NBC44 (Beckman Coulter) according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint.¹⁵ Isolates were tested for extended spectrum beta-lactamases (ESBL) production using E-test ESBL stripes (bioMérieux) and the double-disk synergy test with aztreonam and amoxicillin/clavulanic acid. Isolates having a MIC > 1 mg/L to imipenem or meropenem and > 0.5 mg/L to ertapenem were confirmed by PCR (OXA-48, VIM, KPC, NDM specific primers) with OXVIKPN® real time PCR kit (Progenie Molecular, Spain).

Genetic relationships between isolates were determined by multilocus-sequence typing and automated repetitive-sequence-based PCR in *Klebsiella pneumoniae* using the DiversiLab® (bioMérieux) system.

Outcome parameters

Primary outcome was death within 30 days after the first positive CRE blood culture. Relationship between death and BSI episode (directly related or not directly related) was established by two independent investigators, by reviewing hospital medical records.

Statistical analysis

Categorical variables were presented as absolute frequencies and percentages. Continuous variables were presented as the mean or median, with its standard deviation or ranges, respectively. Categorical variables were compared using chi-square test or Fisher's Exact test, as appropriate. Continuous variables were compared by Student's t test or Mann-Whitney U test according to their distribution. Univariate analysis was conducted to evaluate different possible factors related to mortality. The survival analysis was carried

out by means of the Kaplan-Meier analysis and "log-rank test" was performed to compare survival functions. A two-tailed P value < 0.05 was considered statistically significant. All statistical analysis was performed using SAS 9.3 (SAS Institute, Cary, NC, USA).

Ethics

HULP Institutional Review Board evaluated and approved the study protocol. All collected data were anonymized. Given its observational retrospective design, written informed consent was waived.

Results

Clinical and epidemiological characteristics

Of 2842 positive blood cultures in children during the study period, 928 (32.7%) were Enterobacteriaceae and 38 (1.3%) were CRE isolates that met inclusion criteria (Table 1). Most cases were detected between 2010 and 2015 (73.6%). Mean age was 2.2 years (DS 3.2, range 0-14.5) and patients were predominantly female (55.3%).

No community-acquired cases were detected. Twenty-nine (76.3%) cases were hospital-acquired infections and 9 (23.7%) were related to healthcare.

In regard to underlying conditions, 20 patients (52.6%) had received a transplant. Solid organ transplant was documented in 13 (9 liver, 3 multivisceral and 1 kidney), an allogenic hematopoietic stem cell transplantation in 6 patients and 1 patient had received both (multivisceral and allogeneic hematopoietic stem cell transplantation). Other medical conditions were: heart disease (5/38, 13.2%), neurological (4/38; 10.5%), respiratory (4/38, 10.5%), urological (3/38, 7.9%), digestive (3/38, 7.9%) and malignancy (one hematologic and one solid organ tumor). Fourteen (36.8%) patients were born prematurely.

At the time of bacteremia, 51.7% of patients with hospital-acquired disease were hospitalized in intensive care units (8 in PICU, 7 in NICU), 41.4% in a medical ward and 6.9% were in a surgical ward (Post-Anesthesia Care Unit).

The rate of previous antibiotic exposure, indwelling devices and other possible risk factors for CRE infection are shown in Table 2.

Regarding the source of bacteremia, the intestinal tract was found to be the most common origin causing 11 cases (26.3%), followed by central venous catheter-related bacteremia in 8 (21.1%) and hepatobiliary origin in 6 (5.8%) patients. Three (7.9%) children had urinary tract infection and one patient had a peritoneal catheter-related infection. Only one patient had ventilator-associated pneumonia. The origin remained unknown in 8 (21.1%) cases.

As per severity of disease, 32 (84.2%) patients with CRE BSI met systemic inflammatory response syndrome (SIRS) criteria of which 8 (21.1%) presented as septic shock.

Microbiological results

The isolated bacteria, resistance mechanisms and susceptibility to antimicrobials are shown in Table 3.

Treatment and outcomes

Crude mortality within 30 days from onset of BSI was 18.4% (7/38). Death was considered directly related to the BSI episode in 10.5% of total cases, based on clinical judgment.

Before antibiotic susceptibility test results, 10 (26.3%) children received microbiologically inappropriate empiric therapy (no active antibiotic) while the remaining 28 (73.7%) patients were treated with at least one active antibiotic. In 23 (60.5%) cases a carbapenem

was used before knowing antibiotic susceptibilities. Median duration of empiric treatment was 3 days (IQR 2-5). Optimal early source control was performed in 23.7% (9/38).

Thirty-six (94.7%) patients received microbiologically appropriate targeted therapy and 15 of them (39.5%) were clinically adequately treated with at least two active antibiotics, at a proper dosage and route according to the source of infection.

In univariate analysis, we found a significantly higher mortality rate in patients admitted to neonatal and intensive care units at the time of BSI onset. Including one active antibiotic in the empiric therapy showed to decrease mortality risk in a 92.4% compared to non-active antibiotic (HR 0.076; IC 95% 0.012-0.494). There was no difference in survival depending on meropenem MIC and neither between patients who received meropenem as empiric therapy and those who not. Attending targeted treatment, we did not find differences when monotherapy was used versus combination therapy and the use of meropenem did not prove to improve survival either (Table 4, Figure 1).

Discussion

In the present study, we report 38 cases of CRE bacteremia in pediatric population. To the best of our knowledge, this is the largest current pediatric cohort reported in Europe. Novel agents (ceftazidime-avibactam, aztreonam-avibactam, cefiderocol, etc.) were not available during the study period, so only classical therapeutic agents were used. VIM-type metallo-beta-lactamases were the predominant resistance mechanism in our series, as they were present in 35 of the 38 strains. These VIM-type enzymes were first discovered in Europe in the 1990s and have been reported worldwide in the recent multidrug-resistant Enterobacteriaceae crisis, although the Mediterranean basin and the Middle East are the predominant areas.¹⁶ Most of our cases (73.6%) were detected between 2010 and 2015,

due to a VIM 1 *Klebsiella pneumoniae* ST-54 outbreak during 2010 and an OXA-48 *Klebsiella pneumoniae* ST-11 outbreak in 2012. Antimicrobial stewardship program initiatives in children emerged in 2014 in our hospital, primarily focused on PICU patients so we only found one CRE BSI after 2015.

All episodes of infection in our study were either hospital-acquired or associated with healthcare as in other similar series.^{3,17} Regarding risk factors of CRE BSI, we found that those children who developed CRE BSI had multiple comorbidities, most of them (52.6%) had received a transplant since our hospital is National Referral Hospital for pediatric transplantation. Of note, 94.7% of patients were carriers of indwelling devices. In addition, they often had exposure to carbapenems in the previous 6 months (50%).

The 30-day mortality rate in our study (18.4%) is not as high as compared with previous reports, ranged from 18.5 to 52%.^{5,18-20} Grouping data from those reports and our cohort, mortality rate is 31.8% in pediatric CRE bacteremia, although important differences between series are obvious, including different resistance mechanisms or bacteremia severity. For instance, our lower mortality rate could be related to the relatively low rate of severe bacteremia in our series (21.1% had septic shock) and also to the fact that many strains were susceptible to aminoglycosides (81.6%), offering therapeutic options. In India, Nabarro et al. found a mortality rate of 52%, but resistance to aminoglycosides in their cohort was up to 90%.⁵ In a recent study in Chinese pediatric population with carbapenem-resistant *K. pneumoniae* BSI, mortality rate was similar than ours in relation to low clinical severity and hematological malignancies predominance whose empirical therapy used to be more effective in covering multidrug-resistant bacteria.¹⁸ In a meta-analysis of carbapenem-resistant *K. pneumoniae* infections, mortality was not shown to be lower in VIM-producing compared to KPC. Therefore it is unlikely that the VIM predominant resistance mechanism in our cohort explains our lower mortality rate.²¹

We have found a relationship between increased 30 day-mortality and inadequate empirical antibiotic therapy (no active agent), as was shown in previous studies.²² A recent report by Lodise et al. has established that delayed appropriate therapy may be a more important driver of outcomes than CRE itself.²³ However, Zhang et al. did not identify an association between non-active empirical antibiotic agents and mortality in children.¹⁸ Of note, 52.6% of patients in our cohort had been colonized or infected by a CRE before, as systematic CRE colonization screening in our hospital is performed since 2010 in many units. In adults, Girmenia et al. showed a rate of CRE infection in previously colonized-patients of 10% for immunocompetent, 25% for those with neutropenia, 26% for auto-SCT (stem cells transplant) and 39% for allo-SCT.²⁴ In our pediatric hospital, an infection rate of 13% has been established in patients with previous VIM-type CRE colonization²⁵, but from our knowledge no pediatric data has set which colonized children are at a higher risk to develop an infection. As many patients in our cohort were previously CRE colonized and active antibiotic in empiric therapy showed to decrease mortality risk in a 92.4% compared to non-active antibiotic, antimicrobial stewardship guided antibiogram in colonized stools from selected highly-risk patients might be an interesting strategy to improve CRE BSI prognosis. However, rapid diagnostic testing aiming to reduce the time to effective therapy in antimicrobial stewardship programs would be the most desirable approach.²⁶

Patients admitted to neonatal units and to intensive care units also had significant higher mortality rates in our cohort. Of note, in our survival analysis, there was no evidence of higher mortality in patients with isolated *Klebsiella* spp. strains. No source of infection showed relation to mortality either. Relationship between meropenem MIC and increased mortality has previously been described in adults and Nabarro and Zhang also found statistically increased mortality rate in pediatric patients with CRE BSI with a meropenem

MIC > 8mg/L.^{5,18} Nevertheless, in our cohort meropenem MIC > 8 was not predictive of higher mortality. Empiric antibiotic therapy that included meropenem was also not protective in Zhang's et al. report. Regarding the use of aminoglycosides as empiric treatment, we did not find differences in mortality either.

In adults, retrospective observational studies have suggested improved survival in patients receiving combinations of two or more in vitro active antibiotics, mostly among patients with a high probability of death.⁶ These data have been extrapolated to children with a number of authors suggesting use of combination antibiotics in CRE.⁸ The few pediatric series so far show controversy in this aspect. In our study, targeted treatment with combinations of two or more active agents did not lead to higher survival than monotherapy, as has been shown in a recent clinical trial in adults, where combination therapy was not superior to monotherapy.²⁷ However, most infections in Paul et al. trial (77%) were caused by *Acinetobacter baumannii* so CRE might have been under-represented. The inclusion of meropenem in the targeted therapy also showed no survival improvement in our cohort.

Our study has some limitations. It is a retrospective study of a single cohort from just one center so the sample size is limited, although it is the largest pediatric series reported in Europe so far. This may have influenced the statistical power to identify risk factors and predictors of mortality. Moreover, the high proportion of VIM-producing Enterobacteriaceae in our cohort leads to results that may not be representative for all CRE. Regarding surveillance analysis, our low mortality rate decreases the reliability of results and we have not used severity scores. Nevertheless, given the scarcity of literature on this important subject, mostly in Western Europe, we believe it offers useful insights into the management of CRE BSI in children.

The findings of this study suggest CRE BSI are a growing problem in pediatric patients with comorbidities and underlying devices. The independent factor more related to 30-day mortality in our cohort was success in empiric treatment with at least one active antibiotic. Antimicrobial stewardship strategies focusing on the adequacy of empiric therapy are needed in CRE BSI. Combination antibiotic targeted treatment and a low Meropenem MIC were not related to improved survival in our cohort but sample size might limit these findings.

Funding

This work was not economical supported by any institution.

Transparency declarations

María Fátima Ara-Montojo and Luis Escosa-García contributed equally to this article and both should be considered first author. We have nothing to declare.

Bibliography

1. Montagnani C, Prato M, Scolfaro C, et al. Carbapenem-resistant enterobacteriaceae infections in children: An Italian retrospective multicenter study. *Pediatr Infect Dis J.* 2016;35(8):862-868. doi:10.1097/INF.0000000000001188
2. Logan LK, Renschler JP, Gandra S, Weinstein RA LR. Carbapenem-Resistant Enterobacteriaceae in Children, United States, 1999–2012. *Emerg Infect Dis.* 2015;21(11):2014-2021. doi:10.3201/eid2111.150548
3. Díaz A, Ortiz DC, Trujillo M, Garcés C, Jaimes F, Restrepo AV. Clinical characteristics of carbapenem-resistant *Klebsiella pneumoniae* infections in ill and colonized children in Colombia. *Pediatr Infect Dis J.* 2016;35(3):237-241. doi:10.1097/INF.0000000000000987
4. Chiotos K, Tamma PD, Flett KB, et al. Multicenter study of the risk factors for colonization or infection with carbapenem-resistant Enterobacteriaceae in children. *Antimicrob Agents Chemother.* 2017;61(12):1-9. doi:10.1128/AAC.01440-17
5. Nabarro LEB, Shankar C, Pragasaam AK, et al. Clinical and Bacterial Risk Factors for Mortality in Children with Carbapenem-resistant Enterobacteriaceae Bloodstream Infections in India. *Pediatr Infect Dis J.* 2017;36(6):e161-e166. doi:10.1097/INF.0000000000001499
6. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. *Lancet Infect Dis.* 2017;17(7):726-734. doi:10.1016/S1473-3099(17)30228-1

7. Daikos GL, Tsaousi S, Tzouveleakis LS, et al. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. *Antimicrob Agents Chemother*. 2014;58(4):2322-2328. doi:10.1128/AAC.02166-13
8. Hsu AJ, Tamma PD. Treatment of multidrug-resistant gram-negative infections in children. *Clin Infect Dis*. 2014;58(10):1439-1448. doi:10.1093/cid/ciu069
9. Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children. 2019;(Xx Xxxx):1-11. doi:10.1093/jpids/piz085
10. Aguilera-Alonso D1, Escosa-García L2, Saavedra-Lozano J3, Cercenado E4 B-AF. Carbapenem-Resistant Gram-Negative Bacterial Infections in Children. *Antimicrob Agents Chemother*. 2020;64(3). doi:10.1128/AAC.02183-19
11. Centers for Disease Control and Prevention. CDC. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). *Natl Cent Emerg Zoonotic Infect Dis*. 2014;(November):24. https://www.osha.gov/SLTC/ebola/control_prevention.html.
12. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. *Ann Intern Med [Internet]*. 2002;137(10):791-797. doi:10.7326/0003-4819-137-10-200211190-00007
13. Glodstein, B., Giroir, B., & Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit Care Med*. 2005;6(1):96.

14. FA M. IDSA guidelines for the diagnosis and management of intravascular catheter-related bloodstream infection. *Clin Infect Dis*. 2009;49(11):1770-1771.
doi:10.1086/648112
15. EUCAST Breakpoint tables v 8.1. http://www.eucast.org/clinical_breakpoints/.
Published 2018.
16. Cornaglia G, Giamarellou H, Rossolini GM. Metallo- β -lactamases: A last frontier for β -lactams? *Lancet Infect Dis*. 2011;11(5):381-393. doi:10.1016/S1473-3099(11)70056-1
17. Malande OO, Du Plessis A, Rip D, Bamford C, Eley B. Invasive carbapenem-resistant Enterobacteriaceae infection at a paediatric hospital: A case series. *South African Med J*. 2016;106(9):877. doi:10.7196/SAMJ.2016.v106i9.11028
18. Zhang Y, Guo LY, Song WQ, Wang Y, Dong F, Liu G. Risk factors for carbapenem-resistant *K. pneumoniae* bloodstream infection and predictors of mortality in Chinese paediatric patients. *BMC Infect Dis*. 2018;18(1):1-10.
doi:10.1186/s12879-018-3160-3
19. Maltezou HC, Kontopidou F, Katerelos P, Daikos G, Roilides E, Theodoridou M. Infections caused by carbapenem-resistant gram-negative pathogens in hospitalized children. *Pediatr Infect Dis J*. 2013;32(4):151-154.
doi:10.1097/INF.0b013e3182804b49
20. Ozsurekci Y, Aykac K, Cengiz AB, et al. Bloodstream infections in children caused by carbapenem-resistant versus carbapenem-susceptible gram-negative microorganisms: Risk factors and outcome. *Diagn Microbiol Infect Dis*. 2017;87(4):359-364. doi:10.1016/j.diagmicrobio.2016.12.013

21. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant *Klebsiella pneumoniae*. *Ann Clin Microbiol Antimicrob*. 2017;16(1):1-12. doi:10.1186/s12941-017-0191-3
22. Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant *Klebsiella pneumoniae* in high-risk haematological patients: Factors favouring spread, risk factors and outcome of carbapenem-resistant *Klebsiella pneumoniae* bacteremias. *BMC Infect Dis*. 2017;17(1):1-12. doi:10.1186/s12879-017-2297-9
23. Lodise T, Sciences H, Bonine NG, et al. Antimicrobial Resistance or Delayed Appropriate Therapy—Does One Influence Outcomes More Than the Other among Patients with Serious Infections due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae? *Open Forum Infect Dis*. 2019;ofz194(Major Article).
24. Girmenia C, Rossolini GM, Piciocchi A, et al. Infections by carbapenem-resistant *Klebsiella pneumoniae* in SCT recipients: A nationwide retrospective survey from Italy. *Bone Marrow Transplant*. 2015;50(2):282-288. doi:10.1038/bmt.2014.231
25. González-rubio R, Parra-blázquez D, San-juan-sanz I, Ruiz-carrascoso G, Gallego S, Escosa-garcía L. Original Evolución de la incidencia de pacientes con colonización e infección por bacterias productoras de carbapenemasas VIM en un hospital pediátrico en España. 2019;32(1):60-67.
26. Timbrook TT, Morton JB, Mcconeghy KW, Caffrey AR, Mylonakis E, Laplante KL. The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections□: A Systematic Review and Meta-analysis. 2017;64:15-23. doi:10.1093/cid/ciw649

27. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. *Lancet Infect Dis*. 2018;18(4):391-400. doi:10.1016/S1473-3099(18)30099-9

	Age at admission	Sex	Department	Bacteremia	Microorganism	Source	Carbapenem Resistance	ESBL	Exitus at 30th day	Sepsis /shock	Days from admission to BSI	Days from BSI to discharge / death	Empirical Treatment (ACTIVE AGAINST GRAM NEGATIVE BACTERIA)	Targeted Treatment
1	5 m	F	Post-anesthesia Care Unit	HA	<i>K. pneumoniae</i>	Gut	VIM	☐	A	☐	106	392	Meropenem	Meropenem + Amikacin + Ciprofloxacin
2	4 m	M	Post-anesthesia Care Unit	HA	<i>K. pneumoniae</i>	Catheter related	VIM		†		22	3	Meropenem + Amikacin	Meropenem + Amikacin
3	4 y	M	Hepatology Ward	HCA	<i>K. oxytoca</i>	Hepatobiliar	VIM		A	☐	0	21	Cefotaxime	Meropenem + Amikacin
4	5 m	M	PICU	HA	<i>C. freundii</i>	Hepatobiliar	VIM		A		17	95	Meropenem + Amikacin	Meropenem + Amikacin
5	14 m	F	Hepatology Ward	HA	<i>K. pneumoniae</i>	Hepatobiliar	VIM	☐	A	☐	110	152	Meropenem	Meropenem + Amikacin
6	3 y	F	PICU	HA	<i>K. pneumoniae</i>	Hepatobiliar	VIM	☐	A	☐	51	30	Gentamicin + Ciprofloxacin	Ciprofloxacin
7	3 m	M	PICU	HA	<i>K. pneumoniae</i>	Catheter related	VIM		A	☐	29	5	None	Amikacin
8	3 y	F	Hepatology Ward	HA	<i>S. ureilytica</i>	Gut	VIM	☐	A		126	23	Cefepime + Colistin	Ciprofloxacin
9	4 m	M	Neonatal Unit	HA	<i>K. pneumoniae</i>	Unknown	VIM		†	☐	109	22	Meropenem + Amikacin	Meropenem + Amikacin
10	2 m	F	Neonatal Unit	HA	<i>K. pneumoniae</i>	Unknown	Porins resistance	☐	A	☐	355	70	Meropenem	Meropenem + Amikacin
11	18 d	M	Neonatal Unit	HA	<i>K. pneumoniae</i>	Gut	VIM		†	☐	2	3	Cefotaxime + Meropenem	
12	59 d	F	Neonatal Unit	HA	<i>K. pneumoniae</i>	Unknown	OXA-48	☐	†	☐	59	22	Cefotaxime	Amikacin
13	5 m	M	Neonatal Unit	HA	<i>E. cloacae</i>	Gut	VIM		A	☐	150	22	Amikacin	Amikacin
14	75 d	M	Neonatal Unit	HA	<i>K. pneumoniae</i>	UTI	OXA-48	☐	A	☐	75	226	Meropenem	Meropenem + Amikacin
15	6 m	M	PICU	HA	<i>S. marcescens</i>	Pulmonary	VIM		A		4	18	Cefotaxime	Cefotaxime + Gentamicin + Aztreonam
16	17 m	F	Haemato-oncology Ward	HA	<i>S. marcescens</i>	Unknown	VIM		A	☐	8	17	Meropenem + Amikacin	Meropenem + Amikacin
17	7 m	F	Haemato-oncology Ward	HA	<i>k. pneumoniae</i>	Unknown	VIM		A		21	375	Meropenem + Amikacin	Meropenem + Amikacin
18	14 y	M	Haemato-oncology Ward	HA	<i>E. cloacae</i>	Unknown	VIM	☐	A	☐	60	31	Cefepime + Meropenem	Amikacin + Ciprofloxacin
19	10 y	F	Haemato-oncology Ward	HA	<i>E. cloacae</i>	Gut	VIM		A	☐	36	17	Meropenem + Cefepime	Meropenem + Ciprofloxacin
20	3 y	M	Haemato-oncology Ward	HA	<i>K. oxytoca</i>	Gut	VIM	☐	A		1	7	Cefixime, Cefotaxime	Ciprofloxacin
21	7 m	M	General Paediatrics Ward	HA	<i>K. pneumoniae</i>	Catheter related	VIM	☐	A	☐	19	21	Meropenem	Ciprofloxacin
22	8 m	F	PICU	HA	<i>K. pneumoniae</i>	Peritonitis	VIM	☐	A	☐	143	4	Meropenem	Meropenem + Colistin
23	4 y	F	Haemato-oncology Ward	HA	<i>E. cloacae</i>	Unknown	VIM		A	☐	60	42	Cefepime + Amikacin	Ciprofloxacin + Amikacin
24	4 y	M	Gastroenterology Ward	HCA	<i>E. coli</i>	Catheter related	VIM		A	☐	0	38	Meropenem + Amikacin	Meropenem + Amikacin
25	2 y	M	Nephrology Ward	HA	<i>K. pneumoniae</i>	UTI	VIM	☐	A	☐	6	12	Amikacin + Ceftazidime	Amikacin + Ciprofloxacin
26	2 y	M	Hepatology Ward	HA	<i>E. cloacae</i>	Hepatobiliar	VIM		A	☐	48	176	Meropenem + Amikacin	Amikacin + Ciprofloxacin
27	2 y	F	PICU	HA	<i>E. cloacae</i>	Pulmonary	VIM		A	☐	26	45	Meropenem + Amikacin	Meropenem + Amikacin + Ciprofloxacin
28	10 m	F	Gastroenterology Ward	HCA	<i>E. aerogenes</i>	Catheter related	VIM		A	☐	1	22	Meropenem + Gentamicin	Gentamicin + Aztreonam
29	6 m	M	PICU	HA	<i>K. pneumoniae</i>	Hepatobiliar	VIM	☐	A	☐	63	64	Meropenem + Colistin	Colistin + Fosfomycin

30	4 y	M	Gastroenterology Ward	HCA	<i>K. pneumoniae</i>	Catheter related	VIM		A	0	50	Amikacin	Amikacin + Aztreonam	
31	15 m	M	Nephrology Ward	HCA	<i>K. pneumoniae</i>	Peritoneal dialysis catheter	VIM		A	1	8	Meropenem + Amikacin	Amikacin + Aztreonam	
32	16 y	M	PICU	HCA	<i>K. pneumoniae</i>	Gut	VIM		†	0	2	Cefepime + Amikacin + Colistin	Colistin + Aztreonam + Fosfomycin	
33	4 y	M	General Pediatrics Ward	HCA	<i>K. pneumoniae</i>	Gut	VIM		A	0	16	Meropenem + Amikacin	Amikacin	
34	22 m	M	Haemato-oncology Ward	HA	<i>K. pneumoniae</i>	Catheter related	VIM	0	A	0	226	Meropenem	Imipenem + Amikacin + Ciprofloxacin	
35	2 y	F	Haemato-oncology Ward	HCA	<i>K. pneumoniae</i>	Catheter related	VIM		A	0	14	Cefepime	Amikacin + Ciprofloxacin	
36	9 y	F	PICU	HA	<i>K. oxytoca</i>	Gut	VIM		†	0	50	Meropenem + Amikacin	Meropenem + Ciprofloxacin + Colistin	
37	10 m	F	Emergency Department	HCA	<i>K. oxytoca</i>	UTI	VIM		A	0	-1	5	Amikacin + Fosfomycin	Cotrimoxazole
38	5 m	F	Neonatal Unit	HA	<i>S. marcescens</i>	Unknown	VIM		†	0	175	30	Ciprofloxacin	Ciprofloxacin

467

468 **TABLE 1.** Clinical features of patients with bacteremia due to CRE. Months (m), female (F), hospital-
469 acquired (HA), alive (A), exitus (†), male (M), years (y), health care associated (HCA), days (d), urinary tract
470 infection (UTI).

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

Risk factor	N (%)	491
	Total N:	38
Any antibiotic exposure (30 previous days)	32 (84.2)	492
Cephalosporin exposure (30 previous days)	19 (50)	493
Carbapenem exposure (6 previous months)	19 (50)	
Admission to a unit with previous CRE cases (12 previous months)	14 (36.8)	494
Previous colonization or infection by CRE	20 (52.6)	495
Surgery	18 (47.4)	496
Central venous catheter	35 (92.1)	
Urinary catheter	20 (52.6)	497
Drainage tube	12 (31.5)	498
Parenteral nutrition	26 (77)	
Mechanical ventilation	18 (47.4)	499
Neutropenia	5 (13.2)	500
Renal failure	9 (23.7)	
		501

TABLE 2. Risk factors related to CRE bacteremia.

Strain		AZT	ERT	IMI	MER	COL	AK	CIP	TYG	FOS
<i>K. pneumoniae</i> VIM (18)	Range MIC	≤1 - >8	1 - >1	2 - >8	≤1 - >8	≤0.5->4	≤2 ->32	≤0,5 ->2	≤1 - >4	≤32->64
	S (%)	50	0	11.1	44.4	83.3	72.2	61.1	77.7	83.3
<i>K. pneumoniae</i> OXA-48 ESBL (2)	Range MIC	>16	>1	2-8	2-8	≤0.5	≤2	>2	4	>64
	S (%)	0	0	50	50	100	100	0	0	0
<i>K. pneumoniae</i> ESBL (1)	MIC	>16	>1	8	8	≤0.5	≤2	>2	≤1	≤16
	S (%)	0	0	0	0	100	100	0	100	100
<i>E. cloacae</i> VIM (6)	Range MIC	≤1 - >8	≤0.5->1	4 - >8	≤1 - >8	≤0.5 ->4	≤2	≤0.5 - 1	≤1	≤16
	S (%)	66.6	50	16.6	50	66.6	100	66.6	100	83.3
<i>K. oxytoca</i> VIM (4)	Range MIC	≤1->32	>32	≤1->8	≤1->8	≤0.5	≤2->32	≤0,5	≤1	≤32->64
	S (%)	50	0	25	50	100	75	100	100	25
<i>S. marcescens</i> VIM (3)	Range MIC	≤1	>1	>8	>8	>2	≤2	≤0,5	≤1	≤32->64
	S (%)	100	0	0	0	0	100	100	66.6	66.6
<i>E.coli</i> VIM (1)	MIC	≤1	1	8	8	≤0.5	≤2	≤0.5	≤1	32
	S I R	S	I	I	I	S	S	S	S	S
<i>C. freundii</i> VIM (1)	MIC	≤1	>1	>8	>8	≤0.5	≤2	≤0.5	≤1	≤16
	S I R	S	R	R	R	S	S	S	S	S
<i>S. ureilytica</i> VIM (1)	MIC	>8	1	>8	2	>4	≤2	≤0,5	≤1	32
	S I R	R	I	R	S	R	S	S	S	S
<i>E. aerogenesa</i> VIM (1)	MIC	>8	1	>8	2	>4	≤2	≤0,5	≤1	32
	S I R	R	I	R	S	R	S	S	S	S
ALL (38)	S (%)	55.3	7.9	13.2	39.5	73.6	84.2	68.4	81.6	71.1
	I (%)	2.6	7.9	36.8	34.2	---	---	---	7.9	---
	R (%)	42.1	84.2	50	26.3	26.3	15.8	31.6	10.5	28.9

515

516

517

518

519

520

521

522

TABLE 3. Resistance of strains to antimicrobials agents. "MIC" is the Minimum Inhibitory Concentration acquired in mg/L; "Range MIC" is the range of Minimum Inhibitory Concentration; "S" stands for susceptible; "I" for intermediate and "R" for resistant, as interpreted according to the EUCAST V 6.0 guidelines. "AZT" for aztreonam, "ERT" for ertapenem, "IMI" for imipenem, "MER" for meropenem, "COL" for colistin, "AK" for amikacin, "CIP" for ciprofloxacin, "TYG" for tygeciline, "FOS" for fosfomycin.

Variable	Survived N=31 (%)	Died N=7 (%)	Hazard ratio (95% CI)	P
Median Age (months)	17.64	4.32		
Male (%)	54.84	57.14		
Klebsiella isolated	19 (61.29)	6 (85.71)		NS
Source of infection:				
Intestinal or hepatobiliary tracts	13 (41.94)	3 (42.86)		NS
Catheter-related	7 (22.58)	1 (14.29)		NS
Urinary tract	3 (9.68)	0 (0)		NS
Pulmonary	2 (6.45)	0 (0)		NS
Peritoneal catheter	1 (3.23)	0 (0)		NS
Unknown	5 (16.13)	3 (42.86)		NS
Neonatal unit admission	3 (9.68)	4 (57.14)	0.197 (0.111-0.956)	0.017
Intensive care unit admission	10 (32.26)	6 (85.71)	0.13 (0-0.984)	0.024
Presentation as sepsis	26 (83.87)	6 (85.71)		NS
Presentation as septic shock	5 (16.13)	3 (42.86)		NS
Meropenem MIC >8 mg/L	8 (25.81)	2 (28.57)		NS
Optimal early source control	8 (25.81)	1 (14.29)		NS
No-active antibiotic in empiric therapy	6 (19.35)	4 (57.14)	0.076 (0.012-0.494)	0.001
Meropenem in empiric therapy	19 (61.29)	4 (57.14)		NS
Aminoglycoside in empiric therapy	15 (48.39)	4 (57.14)		NS
Non-clinically adequately or improvable target therapy	19 (61.29)	3/6 (50)*		NS
Monotherapy in target treatment	16 (51.61)	3/6 (50)*		NS
Meropenem in target therapy	14 (45.16)	4/6 (66.66)*		NS

523

524 **TABLE 4.** Univariate analysis of risk factor associated with 30-day mortality. The survival analysis was
525 carried out by means of the Kaplan-Meier analysis and "log-rank test" was performed to compare the

526 survival functions. A two-tailed P value < 0.05 was considered statistically significant. Non-significant (NS).
 527 *One patient excluded because of death before knowing antibiogram.

536 **FIGURE 1.** Kaplan-Meier curves of different factors and survival at 30 days in patients with CRE
537 bacteremia. Non-significant (NS); Minimum Inhibitory Concentration (MIC)